乳腺癌患者B7-CD28共刺激通路的研究

目的探讨乳腺癌患者外周血中CD2 8表达阳性的T细胞数量和患者乳腺癌原代细胞表面B7 1(CD80 )、B7 2 (CD86 )的表达水平 ,以探讨乳腺癌患者共刺激通路是否异常。方法采用流式细胞技术检测乳腺癌患者外周血中CD2 8阳性T细胞与乳腺癌患者原代细胞B7分子的表达 ,并与乳腺良性疾病作比较。结果乳腺癌患者CD2 8阳性的T细胞数明显低于对照组 (t =2 879,P <0 0 5 ) ,特别是CD4/CD2 8双阳性T细胞数更低于对照组 (t=3 0 17,P <0 0 0 1)。乳腺癌患者原代细胞表面B7 1和B7 2表达水平都低于对照组。结论乳腺癌患者外周血中T细胞低表达CD2 8分子 ,乳腺癌细胞低表达B7分子 ,从而影响B7 CD2 8共刺激通路 ,使T细胞不能有效地清除肿瘤细胞。

A study on the B7-CD28 costimulatory pathway in breast cancer patients

Objective To investigate costimulatory pathway of breast cancer patients, we examined peripheral CD28 positive T lymphocytes and B7 molecules expression on the primary breast cancer cells in patients with breast cancer. MethodsFlow cytometry was used to analyze CD28 and B7 molecules expressed on T lymphocytes and primary breast cancer cells respectively. Results CD28 positive T lymphocytes in breast cancer patients was lower than that in control group (t=2.879,P<0.05), with CD4/CD28 double positive T lymphocytes being much lower (t=3.017,P<0.005). Both B7-1(CD80) and B7-2(CD86) molecules expressed on primary breast cancer cells were lower than that in control group. ConclusionPeripheral T lymphocytes in breast cancer patients express low level of CD28 molecule. Primary breast cancer cells express low level of B7 molecules. Costimulatory pathway dysfunction in breast cancer patients results in T lymphocytes failure against the tumor cells.